Importantly, radiographic and histologic evaluations revealed no adverse effects on lesional activity, suggesting that blockade of FGF23 production from Gαs-mutation bearing osteoprogenitor cells is unlikely to increase FD malignancy risk or lesion progression. The gene discussed is FGF23; the disease is Fabry disease.